Galena Biopharma (GALE) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Noble Financial Keeps Galena (GALE) at 'Buy'; Interim NeuVax Phase 3 Data Now in Focus
May 11, 2016 3:12 PM EDTNoble Financial maintains its Buy rating and $3.50 price target on Galena Biopharma, Inc. (Nasdaq: GALE) following Q1 results and update issued Tuesday night.
Analyst Kumaraguru Raja commented, 70 events reached in March and interim safety and futility analysis announcement expected at end... More
Maxim Group Bullish on Galena Biopharma (GALE) Into Interim Analysis of PRESENT Study
May 11, 2016 7:25 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $4 price target on Galena Biopharma (NASDAQ: GALE), saying it 'offers a PRESENT as the data chain chugs along'. Next up is interim analysis.
Kolbert highlighted:
Galena is now cash rich. Management announced a debt financing (May 10, 2016) with the issuance of $25.5M in debentures (30-month term), bringing in $23.4M in net... More